Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-time Adjusted Survival of Patients With Compensated Viral Cirrhosis.

Date publication

mai 2018

Journal

Gastroenterology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre , Pr DI MARTINO Vincent

Tous les auteurs :
Costentin C, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/29729258

Résumé

Semi-annual surveillance for hepatocellular carcinoma (HCC) is recommended for patients with cirrhosis. We aimed to determine how compliance with HCC surveillance guidelines affects survival times of patients with hepatitis C virus (HCV)- or HBV-associated compensated cirrhosis who developed HCC.

Mots clés

Curative Treatment, Early Detection, Liver Cancer, Screening

Référence

Gastroenterology. 2018 May 2;: